Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

CMS Info Systems और Dr Lal PathLabs Stocks  पर खरीदारी से पहले जानें क्या यहां तेजी नज़र आ रही है या नहीं, देखें वीडियो

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

CMS Info Systems और Dr Lal PathLabs Stocks पर क्या आज बन रहा कमाई का Trade? | CNBC Awaaz

Dr Lal Pathlabs Stock अपने 200 Day Moving Average के नीचे Trade कर रहा है। वहीं Stock में Short Term के लिए Weakness देखने को मिल रही है। इस Stock ने अच्छे Volumes के साथ Sell Off दिखाया है, ऐसे में Stock पर लें सलाह, देखें वीडियो

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Dr Lal Pathlabs Share News: Stock पर काफी Volumes, Short Term पर Weakness, अब आगे के लिए लें सलाह

LIC has invested in Dr Lal PathLabs in the quarter ending with December 2021.

LIC invests, mutual funds increase stake in THIS healthcare firm; have you invested?

LIC has bought 1.12% stake in Dr Lal PathLabs during the October-December 2021 period, BSE data showed

LIC picks up stake in this healthcare stock in December quarter

He has over 21 years of work experience across companies like Sanofi, GSK Pharmaceuticals, Medtronic and Dr. Lal Pathlabs.

Fortis Malar Hospitals appoints Chandrasekar Ramasamy as Whole Time Director and KMP

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

COVID19 को लेकर क्या है Dr Lal Pathlabs की रणनीति? कैसा है नॉन कोविड कारोबार का प्रदर्शन? जानिए Dr Lal PathLabs के CMD  Dr Arvind Lal से। 
#Outlook2022
#DrLalPathlabs

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Outlook 2022 : Covid पर क्या है Dr Lal Pathlabs की Strategy, 2022 में कहां करेंगे Focus? CNBC Awaaz

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Sumit और Neeraj Bajpai की Team से Rajesh Satpute ने Radico Khaitan और Dr Lal Pathlabs  Stocks में खरीदारी की सलाह दी है। जानें कैसे इस Stock में करें खरीदारी, देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Radico Khaitan और Dr Lal Pathlabs बनें Rajesh Satpute के चुनिंदा Stocks | CNBC Awaaz

#CNBCAwaazLive #DrLalPathLabs #ChandanTaparia  #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Dr Lal PathLabs पर मुनाफा आ रहा है। Chandan Taparia ने दी है Buy की सलाह, कैसे बनाएं Strategy? देखें वीडियो.


Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Dr Lal PathLabs Share News: Expert Chandan Taparia ने दी है Buy की सलाह, कैसे बनाएं Strategy?

Is Covid testing becoming more common as a result of the Omicron scare? Do Covid businesses remain resilient? Is the company prepped to manage the Covid test surge? Speaking to ET NOW, Dr. Om Manchanda, Managing Director, Dr. Lal PathLabs, tells us how the diagnostic trend has been so far. The company's capacity has gone up 10-15x in the last 6-7 quarters. It has built a strong capacity to tackle a surge in Covid cases, he explains. Covid allied tests went up in April 2021. Non-Covid business is normalising, he adds. Watch the full interview here to get all the details and more.
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Is India Prepared To Manage Covid Test Surge ? | Dr. Om Manchanda, Dr. Lal PathLabs

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Dr Lal PathLabs पर आज तेजी नज़र आ रही है। Chart का Formation काफी Strong है और आगे भी तेजी का मूड यहां देखने को मिल रहा है। देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Dr Lal PathLabs Share News : Rajesh Satpute ने दी यहां खरीदारी की सलाह, कैसे बनाएं Strategy?

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Ashish Verma और Neeraj Bajpai की Team से आज Rajesh Satpute ने Biocon और Dr Lal PathLabs Stocks पर खरीदारी की राय दी है। जानें इन Stocks में क्या है तेजी की वजह और किस Target और Stop Loss के साथ की जा सकती है खरीदारी, देखें वीडियो
 
Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

Biocon और Dr Lal PathLabs Stocks बनें Rajesh Satpute के चुनिंदा Stocks | CNBC Awaaz

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator. 

Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

CMS Info Systems और Dr Lal PathLabs Stocks पर क्या आज बन रहा कमाई का Trade? | CNBC Awaaz

News Video

Dr Lal Pathlabs Share News: Stock पर काफी Volumes, Short Term पर Weakness, अब आगे के लिए लें सलाह

LIC invests, mutual funds increase stake in THIS healthcare firm; have you invested?

LIC picks up stake in this healthcare stock in December quarter

Fortis Malar Hospitals appoints Chandrasekar Ramasamy as Whole Time Director and KMP

News Video

Outlook 2022 : Covid पर क्या है Dr Lal Pathlabs की Strategy, 2022 में कहां करेंगे Focus? CNBC Awaaz

News Video

Radico Khaitan और Dr Lal Pathlabs बनें Rajesh Satpute के चुनिंदा Stocks | CNBC Awaaz

News Video

Dr Lal PathLabs Share News: Expert Chandan Taparia ने दी है Buy की सलाह, कैसे बनाएं Strategy?

News Video

Is India Prepared To Manage Covid Test Surge ? | Dr. Om Manchanda, Dr. Lal PathLabs

Dr. Lal PathLabs Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

CMS Info Systems और Dr Lal PathLabs Stocks पर क्या आज बन रहा कमाई का Trade? | CNBC Awaaz

News Video

Dr Lal Pathlabs Share News: Stock पर काफी Volumes, Short Term पर Weakness, अब आगे के लिए लें सलाह

LIC invests, mutual funds increase stake in THIS healthcare firm; have you invested?

LIC picks up stake in this healthcare stock in December quarter

Fortis Malar Hospitals appoints Chandrasekar Ramasamy as Whole Time Director and KMP

News Video

Outlook 2022 : Covid पर क्या है Dr Lal Pathlabs की Strategy, 2022 में कहां करेंगे Focus? CNBC Awaaz

News Video

Radico Khaitan और Dr Lal Pathlabs बनें Rajesh Satpute के चुनिंदा Stocks | CNBC Awaaz

News Video

Dr Lal PathLabs Share News: Expert Chandan Taparia ने दी है Buy की सलाह, कैसे बनाएं Strategy?

News Video

Is India Prepared To Manage Covid Test Surge ? | Dr. Om Manchanda, Dr. Lal PathLabs

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock